A 4‐site, single‐visit intradermal postexposure prophylaxis regimen for previously vaccinated patients: experiences with >5000 patients.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 20887204.
- Also identified by DOI 10.1086/656585.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We previously demonstrated that 4‐site, intradermal, single‐visit rabies booster vaccination provides immunogenicity greater than that provided by the standard 2‐booster, 2‐visit regimen. The regimen has been routinely used in 5116 patients since 1998 without any treatment failure. It is not only effective but also saves vaccine costs and transportation expenses and improves compliance.
Medical subject headings
- Immunization, Secondary
- Rabies
- Rabies Vaccines